XML 35 R24.htm IDEA: XBRL DOCUMENT
v3.2.0.727

Basis of Presentation (Narrative) (Details) shares in Millions | 1 Months Ended | 3 Months Ended | 6 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
May. 31, 2014 USD ($) | Jan. 31, 2012 USD ($) | Jan. 31, 2010 right | Jun. 30, 2015 USD ($) drug storage_location | Jun. 30, 2014 USD ($) | Jun. 30, 2015 USD ($) drug storage_location segment customer shares | Jun. 30, 2014 USD ($) shares | Dec. 31, 2014 USD ($) customer | Aug. 31, 2014 USD ($) | Jan. 31, 2011 USD ($)
Earnings (Loss) Per Share |  |  |  |  |  |  |  |  |  |
Common shares excluded from computation | shares |  |  |  |  |  | 3.5 | 0.4 |  |  |
Cash, Cash Equivalents and Short-term Investments |  |  |  |  |  |  |  |  |  |
Maturity period of cash and cash equivalents, maximum |  |  |  |  |  | 3 months |  |  |  |
Maturity period of short term investments, minimum |  |  |  |  |  | 3 months |  |  |  |
Concentrations of Credit Risk |  |  |  |  |  |  |  |  |  |
Product Shelf Life |  |  |  |  |  | 5 years |  |  |  |
Number of Storage Locations | storage_location |  |  |  | 3 |  | 3 |  |  |  |
Accounts receivable |  |  |  | $ 5,532,000 |  | $ 5,532,000 |  | $ 12,634,000 |  |
Inventory, Net [Abstract] |  |  |  |  |  |  |  |  |  |
Inventory write downs |  |  |  | 0 | $ 0 | $ 0 | $ 0 |  |  |
Allowance for Doubtful Accounts |  |  |  |  |  |  |  |  |  |
Accounts receivable outstanding considered past due after period, minimum |  |  |  |  |  | 30 days |  |  |  |
Accounts receivable outstanding considered past due after period, maximum |  |  |  |  |  | 90 days |  |  |  |
Allowance for doubtful accounts |  |  |  | 0 |  | $ 0 |  | 0 |  |
Property and Equipment |  |  |  |  |  |  |  |  |  |
Depreciation |  |  |  | 100,000 | 100,000 | $ 100,000 | 100,000 |  |  |
Goodwill and Other Identifiable Intangible Assets |  |  |  |  |  |  |  |  |  |
Finite-lived intangible asset, useful life |  |  |  |  |  | 20 years |  |  |  |
Amortization expense |  |  |  | 600,000 | 600,000 | $ 1,200,000 | 1,200,000 |  |  |
Amortization Expense |  |  |  |  |  |  |  |  |  |
Amortization expense 2015 |  |  |  | 2,400,000 |  | 2,400,000 |  |  |  |
Amortization expense 2016 |  |  |  | 2,400,000 |  | 2,400,000 |  |  |  |
Amortization expense 2017 |  |  |  | 2,400,000 |  | 2,400,000 |  |  |  |
Amortization expense 2018 |  |  |  | 2,400,000 |  | 2,400,000 |  |  |  |
Amortization expense 2019 |  |  |  | $ 2,400,000 |  | $ 2,400,000 |  |  |  |
Revenue Recognition |  |  |  |  |  |  |  |  |  |
Period allowed for return of products, minimum |  |  |  |  |  | 30 days |  |  |  |
Period allowed for return of products, maximum |  |  |  |  |  | 90 days |  |  |  |
Restocking fee (percent) |  |  |  |  |  | 20.00% |  |  |  |
Discontinued Operations |  |  |  |  |  |  |  |  |  |
Number of drugs included in product line | drug |  |  |  | 4 |  | 4 |  |  |  |
Segment Reporting |  |  |  |  |  |  |  |  |  |
Number of reportable segments | segment |  |  |  |  |  | 2 |  |  |  |
Minimum |  |  |  |  |  |  |  |  |  |
Revenue Recognition |  |  |  |  |  |  |  |  |  |
Period when partenr sales reports are received after end of quarter |  |  |  |  |  | 30 days |  |  |  |
Maximum |  |  |  |  |  |  |  |  |  |
Revenue Recognition |  |  |  |  |  |  |  |  |  |
Period when partenr sales reports are received after end of quarter |  |  |  |  |  | 60 days |  |  |  |
Equipment | Minimum |  |  |  |  |  |  |  |  |  |
Property and Equipment |  |  |  |  |  |  |  |  |  |
Estimated useful life of assets |  |  |  |  |  | 3 years |  |  |  |
Equipment | Maximum |  |  |  |  |  |  |  |  |  |
Property and Equipment |  |  |  |  |  |  |  |  |  |
Estimated useful life of assets |  |  |  |  |  | 10 years |  |  |  |
Cydex Pharmaceuticals, Inc |  |  |  |  |  |  |  |  |  |
Contingent Liabilities |  |  |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  |  |  |  |  | $ 17,600,000
Fair value of liability |  |  |  | $ 10,400,000 |  | $ 10,400,000 |  | 11,500,000 |  |
Contingent liability change in amount |  |  |  | 1,000,000 | 3,200,000 | 2,200,000 | 2,700,000 |  |  |
Cydex Pharmaceuticals, Inc | Guaranteed Payment |  |  |  |  |  |  |  |  |  |
Contingent Liabilities |  |  |  |  |  |  |  |  |  |
Purchase of commercial license rights |  | $ 4,300,000 |  |  |  |  |  |  |  |
Cydex Pharmaceuticals, Inc | Revenue Sharing |  |  |  |  |  |  |  |  |  |
Contingent Liabilities |  |  |  |  |  |  |  |  |  |
Purchase of commercial license rights |  |  |  |  | 1,600,000 | 3,200,000 |  |  |  |
Metabasis Therapeutics |  |  |  |  |  |  |  |  |  |
Contingent Liabilities |  |  |  |  |  |  |  |  |  |
Fair value of liability |  |  |  | 8,400,000 |  | 8,400,000 |  | $ 3,700,000 |  |
Contingent liability change in amount |  |  |  | (6,400,000) | 1,900,000 | $ (5,300,000) | (500,000) |  |  |
Number of contingent value rights | right |  |  | 4 |  |  |  |  |  |  |
Number of contingent value rights per series of contingent value rights | right |  |  | 1 |  |  |  |  |  |  |
Number of contingent value rights issued for each share | right |  |  | 4 |  |  |  |  |  |  |
Contingent value rights, frequency of cash payment |  |  | 6 months |  |  |  |  |  |  |
Accounts Receivable | Customer Concentration Risk |  |  |  |  |  |  |  |  |  |
Concentrations of Credit Risk |  |  |  |  |  |  |  |  |  |
Concentration risk, number of customers | customer |  |  |  |  |  | 1 |  | 2 |  |
Concentration risk, percentage of accounts receivable |  |  |  |  |  | 88.00% |  | 64.00% |  |
Acquired In Process Research And Development |  |  |  |  |  |  |  |  |  |
Acquired In-Process Research and Development |  |  |  |  |  |  |  |  |  |
Impairment of in-process research and development |  |  |  | 0 | $ 0 | $ 0 | $ 0 |  |  |
Omthera Pharmaceuticals |  |  |  |  |  |  |  |  |  |
Milestone Payments |  |  |  |  |  |  |  |  |  |
Event-based payment | $ 1,000,000 |  |  |  |  |  |  |  |  |
Proceeds from Collaborators |  |  |  |  |  |  |  | $ 500,000 |  |
Milestone payment received |  |  |  |  |  | 0 |  | 0 |  |
Collaborative Arrangement, Product | Omthera Pharmaceuticals |  |  |  |  |  |  |  |  |  |
Milestone Payments |  |  |  |  |  |  |  |  |  |
Event-based payment |  |  |  |  |  |  |  | 400,000 |  |
2019 convertible senior notes |  |  |  |  |  |  |  |  |  |
Convertible Debt |  |  |  |  |  |  |  |  |  |
Principal amount outstanding |  |  |  | $ 245,000,000 |  | $ 245,000,000 |  | $ 245,000,000 |  |
2019 convertible senior notes | Senior Notes |  |  |  |  |  |  |  |  |  |
Convertible Debt |  |  |  |  |  |  |  |  |  |
Principal amount outstanding |  |  |  |  |  |  |  |  | $ 245,000,000.0 |
Interest rate |  |  |  |  |  |  |  |  | 0.75% |

X
- Definition Business acquisition contingent consideration, potential cash payment at end of period. + References No definition available. + Details
Name: | lgnd_BusinessAcquisitionContingentConsiderationPotentialCashPaymentAtEndOfPeriod
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Concentration Risk, Number of Customers + References No definition available. + Details
Name: | lgnd_ConcentrationRiskNumberOfCustomers
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Contingent Value Right, Frequency of Cash Payment to Stockholders + References No definition available. + Details
Name: | lgnd_ContingentValueRightFrequencyOfCashPaymentToStockholders
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maturity period of highly liquid securities maximum. + References No definition available. + Details
Name: | lgnd_MaturityPeriodOfHighlyLiquidSecuritiesMaximum
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum period for accounts receivable outstanding to be considered as past due. + References No definition available. + Details
Name: | lgnd_MaximumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone Payments [Abstract] + References No definition available. + Details
Name: | lgnd_MilestonePaymentsAbstract
Namespace Prefix: | lgnd_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Minimum period for accounts receivable outstanding to be considered as past due. + References No definition available. + Details
Name: | lgnd_MinimumPeriodForAccountsReceivableOutstandingToBeConsideredAsPastDue
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non restricted equity and debt securities with maturity period. + References No definition available. + Details
Name: | lgnd_NonRestrictedEquityAndDebtSecuritiesWithMaturityPeriod
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Contingent Value Rights Issued + References No definition available. + Details
Name: | lgnd_NumberOfContingentValueRightsIssued
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Contingent Value Rights per Series of Contingent Value Rights + References No definition available. + Details
Name: | lgnd_NumberOfContingentValueRightsPerSeriesOfContingentValueRights
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Drugs Included in Product Line + References No definition available. + Details
Name: | lgnd_NumberOfDrugsIncludedInProductLine
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of Respective Series of Contingent Value Rights, Issued for Each Share + References No definition available. + Details
Name: | lgnd_NumberOfRespectiveSeriesOfContingentValueRightsIssuedForEachShare
Namespace Prefix: | lgnd_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period allowed for return of products, maximum. + References No definition available. + Details
Name: | lgnd_PeriodAllowedForReturnOfProductsMaximum
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period allowed for return of products, minimum. + References No definition available. + Details
Name: | lgnd_PeriodAllowedForReturnOfProductsMinimum
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Product Shelf Life + References No definition available. + Details
Name: | lgnd_ProductShelfLife
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Licensee Sales Reporting Period + References No definition available. + Details
Name: | lgnd_RevenueRecognitionLicenseeSalesReportingPeriod
Namespace Prefix: | lgnd_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue Recognition, Milestone Payment Received + References No definition available. + Details
Name: | lgnd_RevenueRecognitionMilestonePaymentReceived
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Sales Returns, Restocking Fee, Percent + References No definition available. + Details
Name: | lgnd_SalesReturnsRestockingFeePercent
Namespace Prefix: | lgnd_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Write-off of In-Process Research and Development + References No definition available. + Details
Name: | lgnd_WriteoffofInProcessResearchandDevelopment
Namespace Prefix: | lgnd_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_AccountsReceivableNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an unclassified balance sheet, a valuation allowance for receivables due a company that are expected to be uncollectible. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 310 -SubTopic 10 -Section 50 -Paragraph 4 -URI http://asc.fasb.org/extlink&oid=35738203&loc=d3e5074-111524 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 + Details
Name: | us-gaap_AllowanceForDoubtfulAccountsReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Antidilution -URI http://asc.fasb.org/extlink&oid=6505113 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Diluted Earnings Per Share -URI http://asc.fasb.org/extlink&oid=6510752 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Contingent Stock Agreement -URI http://asc.fasb.org/extlink&oid=6508534 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257 + Details
Name: | us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 4 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph b -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_CommitmentsAndContingenciesDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Face (par) amount of debt instrument at time of issuance. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 55 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=34725769&loc=d3e28878-108400 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 835 -SubTopic 30 -Section 45 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=6451184&loc=d3e28551-108399 + Details
Name: | us-gaap_DebtInstrumentFaceAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contractual interest rate for funds borrowed, under the debt agreement. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.22(a)(1)) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 22 -Article 5 + Details
Name: | us-gaap_DebtInstrumentInterestRateStatedPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3602-108585 + Details
Name: | us-gaap_Depreciation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_EarningsPerShareAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=26713463&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsFutureAmortizationExpenseAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_InventoryNetAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Charge to cost of goods sold that represents the reduction of the carrying amount of inventory, generally attributable to obsolescence or market conditions. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 330 -SubTopic 10 -Section 50 -Paragraph 2 -URI http://asc.fasb.org/extlink&oid=28360613&loc=d3e4542-108314 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.2) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 + Details
Name: | us-gaap_InventoryWriteDown
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_LongtermConvertibleDebtCurrentAndNoncurrentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements. + References No definition available. + Details
Name: | us-gaap_NumberOfReportableSegments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of stores. + References No definition available. + Details
Name: | us-gaap_NumberOfStores
Namespace Prefix: | us-gaap_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3213-108585 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Glossary Investing Activities -URI http://asc.fasb.org/extlink&oid=6516133 + Details
Name: | us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=31042434&loc=d3e3536-108585 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. + References No definition available. + Details
Name: | us-gaap_PropertyPlantAndEquipmentUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.3,4) -URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 4 -Article 5 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Subparagraph a -Article 5 + Details
Name: | us-gaap_ReceivablesNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_ResearchAndDevelopmentAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueRecognitionAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=19771982&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RisksAndUncertaintiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_CydexPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=lgnd_GuaranteedPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContingentConsiderationByTypeAxis=lgnd_RevenueSharingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=lgnd_MetabasisTherapeuticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=lgnd_AcquiredInProcessResearchAndDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=lgnd_OmtheraPharmaceuticalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementProductAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DebtInstrumentAxis=lgnd_A2019ConvertibleSeniorNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |